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INTRODUCTION
The protozoa, as typically delineated in public health, are a nonmonophyletic conglomerate 
of unicellular eukaryotic organisms that are characterized by having animallike affinities. 
Most protozoa that infect the human enteric tract are characterized by having an 
environmentally stable stage such as a cyst or oocyst. Cysts and oocysts confer protection 
from environmental factors, allowing these parasites to infect other susceptible hosts 
through either the water or food-borne routes.
There are several parasitic protozoa that can cause enteric infections in humans, the focus 
here being Cryptosporidium spp, Cyclospora cayetanensis, Giardia duodenalis (syn. 
Giardia lamblia, Giardia intestinalis), and Cystoisospora belli (previously Isospora belli). 
Infections are usually characterized by gastrointestinal clinical manifestations that may 
include diarrhea, vomiting, abdominal cramps, and general malaise.1,2 Three of these 
protozoa, Cryptosporidium, Cyclospora, and Cystoisospora, were previously classified as 
coccidian parasites because of their intracellular location (these parasite infect enterocytes) 
and a complex life cycle that includes asexual (meronts) and sexual (microgametocytes and 
macrogametocytes) reproductive stages.3 Giardia is a flagellate, does not invade epithelial 
cells, and reproduces only asexually by binary fission.
The classification of eukaryotic parasites is in frequent revision because of modern 
systematics that incorporate bioinformatic data and cladistics classification into the 
traditional morphometric-based taxonomy. As of 2012, the formerly known coccidians are 
classified in the subgroup Apicomplexa, with Cyclospora and Cystoisospora being classified 
as Eimeriorinas (the sporozoites, which are the infective stages, are always enclosed in 
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sporocysts within an oocyst) and Cryptosporidium grouped alone as a single clade (oocysts 
without sporocysts, containing 4 naked sporozoites).4
These parasites produce resistant stages (cysts in Giardia,5 oocysts in the coccidia), which 
are released into the environment. The excretion intensity of these parasites can vary 
significantly, from very high to low, and can be sporadic.6 Therefore, the diagnostic success 
of a single stool sample can be suboptimal.7 It is currently recommended to test 3 samples,8 
ideally collected every other day, over a period of at least 1 week.9
Samples have to be properly preserved to assure success of the assays to be conducted. The 
most widely used method relies on a 2-vial collection system with sodium acetate-acetic 
acid-formalin (SAF); 10% buffered formalin; polyvinyl alcohol (PVA) containing fixatives 
such as mercury, zinc, or copper (Zn PVA, Cu PVA); or Schaudinn fluid. However, there is 
a trend to minimize the use of formalin (because of toxicity) and mercury (environmental 
impact)10; however, those alternatives may not always have high parasite recovery rates and 
not are always compatible with immunoassays.7
See Appendix 1 for laboratory procedures for the microscopic detection of coccidian 
parasites (Cryptosporidium spp, C cayetanensis, and C belli).
CRYPTOSPORIDIUM SPP
The genus Cryptosporidium was first described in 1910 by Tyzzer,11 who in 1912 also 
described Cryptosporidium parvum in the small intestine of mice.12 For several decades, 
human cryptosporidiosis was considered a benign self-resolving infection that was caused 
by C parvum.13 This parasite was considered to have the potential to infect a broad range of 
mammalian species. With the advent of the human immunodeficiency virus (HIV)/AIDS 
epidemic, cryptosporidiosis became an important infection, where immunocompromised 
patients developed nonretractable life-threatening diarrhea.14,15 Cryptosporidiosis was 
classified as opportunistic infection and also as an AIDS-defining illness.16 Given its public 
health importance, numerous studies were conducted to better understand its pathogenesis, 
transmission routes, therapeutic approaches, and disease-prevention strategies. The renewed 
interest led to important discoveries that highlighted the importance of the immune system, 
more specifically CD4 cells, in the clearance of infections.17,18 It was also confirmed that its 
primary route of transmission was waterborne and that people with immune deficiencies 
other than HIV were also at risk of severe disease.19,20
Data from studies using DNA-based methods started to provide evidence that not all isolates 
of Cryptosporidium previously identified as C parvum had the same DNA signatures.21 
Further studies showed that the parasites previously described as C parvum may actually 
encompass several species that were morphologically identical; however, DNA data showed 
distinct genetic signatures and epidemiologic and biological data showed that several 
isolates had defined host specificities.22
Differences in DNA patterns between human and animal isolates were reported using whole 
DNA extracts21 and further substantiated using polymerase chain reaction (PCR)-amplified 
regions of the 18s small subunit ribosomal RNA gene.22–24 The systematic use of DNA-
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based methods, in conjunction with biological and epidemiologic studies, have led to a 
major revision of the genus Cryptosporidium.25–28
At present, there are 26 different species of Cryptosporidium.29 The species most frequently 
detected in humans are Cryptosporidium hominis, an anthroponotic parasite (infecting only 
humans), and C parvum, a zoonotic species. It should be noted that C parvum is most 
frequently detected in weaned calves but not in heifers or older cattle.30 These 2 species of 
Cryptosporidium have different epidemiologic distributions. Both parasites are frequent in 
European countries, whereas C parvum has been the species more frequently reported in the 
Middle East. In the United States, other industrialized nations, and other developing 
countries, C hominis is the parasite most frequently detected in people. Species less 
frequently reported are Cryptosporidium ubiquitum (previously described as cervine 
genotype) mainly in industrialized nations, Cryptosporidium canis and Cryptosporidium 
felis in nonindustrialized countries, and Cryptosporidium cuniculus, primarily in the United 
Kingdom. Other species with limited number of cases reported are Cryptosporidium 
meleagridis, Cryptosporidium viatorum, Cryptosporidium suis, Cryptosporidium muris, 
Cryptosporidium fayeri, Cryptosporidium andersoni, Cryptosporidium bovis, 
Cryptosporidium tyzzeri, Cryptosporidium erinacei, Cryptosporidium scrofarum, and 
Cryptosporidium xiaoi.31
Life Cycle and Biology
The latest classification of eukaryotic organisms places Cryptosporidium in its own clade, 
which is outside the Coccidia proper.4 Cryptosporidium spp are morphologically 
characterized by the presence of an attachment feeder organelle, location in the host’s cells 
(intracellular, but extracytoplasmic), presence of 2 functional types of oocysts (thin and 
thick walled), presence of a gamontlike extracellular stage, and lack of sporocysts, 
microphyles, and polar granules.32–35
Only 1 host is required for Cryptosporidium to complete its life cycle. Fully sporulated, 
thick-walled oocysts are shed in the feces. Unlike other intestinal coccidia, oocysts of 
Cryptosporidium spp are immediately infective when shed from the host. Infection occurs 
after the ingestion of oocysts in fecal-contaminated food, water, and fomites. After ingestion 
by a suitable host, oocysts excyst in the small intestine, releasing sporozoites. The 
sporozoites parasitize the epithelial cells of the intestinal tract and produce a parasitophorous 
vacuole located between the host cell’s cytoplasm and cell membrane. This unique 
intracellular but extracytoplasmatic location allows the parasite to derive nutrients via a 
feeder organelle.
Within the parasitophorous vacuole, sporozoites undergo asexual cycles of merogony. 
Mature meronts rupture from the infected host cell and take 1 of 2 pathways. Type I meronts 
give rise to merozoites that perpetuate the asexual cycle in the surrounding host cells. Type 
II meronts give rise to merozoites that initiate the sexual cycle by producing microgametes 
(males) or macrogametes (females). Fertilization of macrogametes by microgametes results 
in the formation of zygotes. Zygotes differentiate into 4 sporozoites and develop a cyst wall, 
becoming oocysts. Thin-walled oocysts rupture in the lumen of the intestine and perpetuate 
Cama and Mathison Page 3













autoinfection, whereas thick-walled oocysts are shed in stool where they are immediately 
infectious to a susceptible host.36,37
Epidemiology
Cryptosporidiosis is ubiquitous and is reported worldwide. It is primarily transmitted 
through the waterborne route38; however, food-borne39–41 or direct-contact transmission can 
also occur.42–44 Overall, the frequency of cryptosporidiosis has shown distinct patterns 
between areas with high endemicity, mainly associated with other enteropathogens, and 
areas with low endemicity, mainly from industrialized countries, where infections are 
usually in low levels. There are some patterns for seasonality. For example, in European 
countries and New Zealand, C hominis was more frequently detected in fall, whereas C 
parvum was more frequently reported in spring.45
In areas of high endemicity, first cryptosporidial infections usually occur in young children, 
mainly by age 2 years. Most first infections are symptomatic, primarily associated with 
diarrhea. Detectable infections decrease with age, and cases of cryptosporidiosis are highly 
infrequent in children. Meanwhile, the adults living in the same settings usually do not have 
detectable cryptosporidiosis. Some seasonal trends have been reported.1
In industrialized nations, infections have been reported in people of all ages. 
Cryptosporidiosis in the United States is a reportable disease. The number of cases is 
consistently greater during the summer months, when outbreaks associated with the use of 
recreational waters are reported, and more frequently among children aged 1 to 9 years, 
followed by young adults (aged about 25–39 years).46–48 Foodborne outbreaks have been 
associated with the consumption of raw or undercooked foods49 or unpasteurized drinks.50
Clinical Manifestations
Immunocompetent people and children usually present short-term, self-limited watery 
diarrhea that may be accompanied with nausea and vomiting, which can lead to 
dehydration.1,51 People with immune deficiencies, especially with low CD4+ counts 
(<140/mm3)17 may present chronic and debilitating disease, which can lead to life-
threatening syndromes.52
Treatment
Multiple drugs or immunotherapeutic compounds have been developed or tested for the 
treatment of human cryptosporidiosis. Very few of these compounds have shown therapeutic 
efficacy. Rehydration through the oral route is the most widely used intervention. Thus far, 
only nitazoxanide has been approved by the US Food and Drug Administration (FDA) for 
the treatment of Cryptosporidium infections in people.53 This product has shown to shorten 
the duration of diarrhea and parasite excretion, although it is not highly efficacious in the 
treatment of cryptosporidiosis in people with immune deficiencies.54 In people with HIV 
infections and low CD4 counts, the preferred treatment and preventative measure would be 
the administration of highly active antiretroviral therapies (HAART). Relapses are frequent 
when patients discontinue HAART.
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Microscopy—Cryptosporidium spp are not readily detected by routine O&P testing such 
as formalin-ethyl acetate (FEA) concentration or trichrome staining.9 Visualization of 
oocysts require special staining, such as Kinyoun MAF, Zieh-Neelsen acid-fast, or safranin 
(Fig. 1). Cryptosporidium may also be detected by the aurimine O stain used for 
mycobacteria. Direct fluorescent antibody (DFA) microscopy kits are also helpful for 
detection and specimen screening. Unlike several other coccidians, Cryptosporidium spp do 
not autofluoresce under ultraviolet (UV) light.7,9,55
Antigen detection and rapid/point-of-care diagnosis—These assays are based on 
the detection of parasite antigens that can be detected in stool specimens. They have the 
advantage of simplicity and not requiring specialized trained personnel, and several products 
are already approved for clinical diagnosis (Table 1).56 Disadvantages are that the species 
identification or quantification of parasite loads is not possible.
Molecular diagnosis—DNA-based methods are primarily used for species identification 
and molecular typing. PCR and PCR-related methods have been developed for the detection 
and identification of species within Cryptosporidium spp. Several protocols for PCR 
detection of Cryptosporidium DNA have been made available; however, none of these 
methods has received approval from FDA or for use of the European Conformity (CE) logo. 
These protocols allow the identification of Cryptosporidium that are of public health 
importance. Methods using PCR amplification followed by restriction fragment length 
polymorphism have been developed for the detection and differentiation of Cryptosporidium 
at the species level. Most of these techniques are based on the amplification of the small-
subunit (SSU) rRNA gene.57 There are other PCR-based protocols that have been designed 
for the detection and differentiation of C parvum and C hominis, the 2 most frequent species 
affecting humans. However, these protocols cannot detect or differentiate other 
Cryptosporidium spp or genotypes.45
Subtype analyses, which are based on PCR amplification followed by DNA sequence 
analysis, is a powerful tool for outbreak investigations. Several subtyping tools have also 
been developed to characterize the diversity within C parvum or C hominis.45 This method 
is based on the sequence polymorphism of the GP-60 locus (also known as gp15/45/60, 
gp40/15), which has shown to be a robust tool in outbreak investigations.44
CYCLOSPORA CAYETANENSIS
This coccidian parasite was described in 1993.2 It is recognized as an important cause of 
food-borne outbreaks, both in the United States as well as in other industrialized nations. 
The name C cayetanensis was first proposed in 1992; however, previous studies reported 
organisms that later have been considered to be similar to Cyclospora.58 However, earlier 
reports hypothesized that those new organisms could belong to a new species of Isospora.58
In 1993, the description of oocysts, which after sporulation had 2 clearly defined sporocysts, 
each with 2 sporozoites, led to the organism’s classification as Cyclospora and to the species 
name C cayetanensis. The genus Cyclospora is currently placed among the Eimeriorina.4,59 
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Molecular data suggest that Cyclospora may actually belong nestled within the genus 
Eimeria.60,61 At present, C cayetanensis is the only species known to infect humans. Three 
other species are known to infect nonhuman primates, all parasites of monkeys in Africa.62
Biology
Cyclospora cayetanensis (Cyclospora) is an anthroponotic parasite. Attempts to infect other 
animal species have proved unsuccessful63; thus, there is no animal model to better 
understand its biology. The live stages of Cyclospora were described from jejunal 
biopsies.64 Infections start when a susceptible person ingests sporulated oocysts, a stage that 
is environmentally resistant. Oocysts are broken in the upper gastrointestinal tract because of 
partial digestion with gastric juices and digestive enzymes, leading to the release of the 2 
internal cysts, called sporocysts, each with 2 infectious stages called sporozoites. On their 
release in the small intestine, the sporozoites infect epithelial cells where they transform into 
merozoites and replicate asexually, also infecting other enterocytes. After asexual 
replications, the merozoites differentiate into sexual stages called microgametocytes and 
macrogametocytes. New oocysts are formed as result of sexual reproduction between the 
microgametocytes and macrogametocytes. Unsporulated (and therefore noninfectious) 
oocysts are eventually released into the environment. Sporulation occurs in the environment. 
The precise factors that cause sporulation are not known, but it is estimated that it occurs in 
about 2 weeks.2,65
Epidemiology
Cyclospora infections have been reported in several areas of the world. It is endemic mainly 
in nonindustrialized nations, whereas sporadic reports associated with outbreaks have been 
frequently reported in industrialized countries.66 In endemic settings, cyclosporiasis is more 
frequent in children between the ages of 2 and 5 years, showing a marked seasonal pattern.67 
For example, in Nepal, there were higher rates of infection during the summer and rainy 
seasons,68 whereas in Peru, most cases were detected between December and May, which 
are warmer months but without rain.67
In industrialized nations, cyclosporiasis has been more frequently reported in the summer 
months and most outbreaks have been traced back to imported fresh products. In the 1990s, 
most reported outbreaks in the United States were linked to imported berries. This trend has 
changed, and during the past 14 years, most outbreaks have been linked to leafy greens 
consumed raw, such as basil and herbs.
Clinical Manifestations and Treatment
Gastrointestinal manifestations associated with cyclosporiasis include diarrhea, fatigue, and 
abdominal cramps, which are most likely reported between 1 and 2 weeks after infection. 
The duration of the patent period and the severity of symptoms are different between people 
living in endemic and nonendemic areas. Infections in endemic settings occur mainly in 
children older than 2 years and are almost never detected after 10 years of age. In these 
cases, infections may resolve spontaneously, and as high as 50% of infected people may not 
show any clinical symptoms. It seems that immunity plays a significant role.
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In industrialized nations, where the parasite is not endemic, most people are likely to be 
naive and infections are almost always symptomatic, lasting 1 to 2 weeks or more. The main 
symptom is diarrhea, which persists if untreated.69 Other symptoms are general malaise, 
lack of energy, loss of appetite, mild fever, nausea, flatulence, and abdominal cramps.67,70
In the case of people with deficits in their immune system, there are anecdotal reports of 
infections with a longer duration, although cyclosporiasis is not considered an opportunistic 
infection in HIV-infected people.71 Treatment is highly effective and is based on the 
administration of sulfamethoxazole trimethoprim (TMP/SMX) orally, twice daily for 7 to 10 
days.72 However, no specific treatment is recommended for people who are allergic to sulfa 
drugs.55
Diagnostic Testing
Microscopy—As with other coccidia, C cayetanensis is not easily detected with traditional 
O&P procedures such as FEA concentration and trichrome stain.55 Oocysts can be better 
visualized in FEA concentrates if viewed under differential interference contrast or phase 
contrast microscopy.2,65 Oocysts can be more easily detected with permanent staining 
methods such as safranin or MAF staining. Oocysts stain red with both stains; however, 
characteristic nonuniform staining is observed with MAF and unstained oocysts are usually 
white and are referred to as ghost forms (see Fig. 1). In the case of safranin, oocysts stain 
more uniformly.55
Another characteristic of C cayetanensis is the autofluorescence of the oocyst wall under 
UV light, using excitation filters of 330 to 365 nm and less intense autofluorescense with 
filters of 450 to 490 nm.2,9,65 Autofluorescence plus morphometric characteristics are 
helpful when detecting Cyclospora (Fig. 2). There are currently no DFA or molecular 
procedures that are approved by the FDA for routine clinical diagnosis of cyclosporiasis.
CYSTOISOSPORA BELLI (PREVIOUSLY ISOSPORA BELLI)
Biology and Taxonomy
Cystoisospora belli is placed among the Eimeriorina along with Cyclospora.4 For several 
decades, C belli was placed in the genus Isospora until morphologic and molecular data 
were used to support its proper classification in the genus Cystoisospora.73,74 This genus 
now includes all previously classified Isospora spp that infect mammals, whereas Isospora 
contains only parasites that infect passeriform birds.74
Life Cycle and Biology
Cystoisospora belli is known to infect only humans and requires only the one host for 
completion of its life cycle, although paratenic hosts may be involved.75 Typically, partially 
sporulated oocysts containing 1 (rarely 2) sporoblast are shed in feces. In the environment, 
the sporoblast divides into 2 sporoblasts, each of which secretes a cell wall to become 
sporocysts. After sporulation, each sporocyst contains 4 sporozoites. Humans become 
infected after ingestion of fully sporulated oocysts, through contaminated food, water, and 
fomites. On ingestion, the sporocysts excyst in the small intestine and release the 
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sporozoites, which invade the host epithelial cells. The sporozoites undergo asexual 
replication called schizogony. Mature schizonts rupture, releasing merozoites that parasitize 
surrounding epithelial cells, perpetuating asexual multiplication. Eventually, multinucleate 
meronts are formed and sexual stages develop. Macrogametocytes are fertilized by 
microgametocytes resulting in formation of the oocyst, which can persist in the environment 
for several weeks or months.55,75,76
Epidemiology
Cystoisospora belli has a worldwide distribution; however, several studies from AIDS 
patients with diarrhea have shown a higher prevalence of cystoisosporiasis among people 
from tropical or subtropical areas.77–79
Clinical Manifestations and Treatment
In immunocompetent people, C belli has been associated with diarrhea, usually lasting 6 to 
10 days, and infections self-resolving in 2 to 3 weeks, although intermittent shedding may 
continue for an additional 2 to −3 weeks. Severe symptoms were reported among people 
with immunocompromised systems, which can lead to life-threatening chronic profuse 
diarrhea.52,80 Treatment is based on TMP/SMX.81
Microscopic Diagnosis
Because of their large size, oocysts of C belli are usually detected during route O&P 
examinations. However, because oocysts tend to be shed in small numbers, repeated stool 
examinations and concentration procedures are recommended. Coccidian-specific stains, 
such as MAF and safranin, are preferred if permanent stains are used for diagnosis (see Fig. 
1). As with C cayetanensis, screening of wet mounts can be enhanced by using UV 
microscopy, with both oocyst and sporoblast/sporocyst walls capable of 
autofluorescence.7,9,75 There are currently no DFA or molecular procedures approved for 
routine clinical diagnosis of cystoisosporiasis.
GIARDIA DUODENALIS
Biology
The protozoan flagellate parasite G duodenalis is a common cause of human diarrheal 
disease worldwide.82 It is transmitted through the fecal-oral route, frequently through 
ingestion of contaminated water and food.6,76,82 This parasite has a direct life cycle, and the 
cysts passed in the feces are immediately infectious. These cysts can remain infectious for 
long periods in moist and cool environments.
Epidemiology
Giardia has a worldwide distribution.83 It affects people of all ages and has an important 
impact on public health. In the United States, it is more frequently reported in children aged 
1 to 9 years.84 This parasite has been associated with major outbreaks and can also be 
present in domestic animals, such as household pets and farm animals. Giardiasis is highly 
underreported, with data from the United States showing that the number of annually 
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reported cases remained steady for several years at around 20,000, whereas the estimated 
number of cases was 2 million.85
Through molecular genotyping methods, G duodenalis has been classified in distinct 
assemblages or genotypes. Assemblages A and B are the most frequently reported in 
humans, either in industrialized or nonindustrialized nations. These assemblages have also 
been reported in cattle, dogs, and cats from different countries around the world. However, 
other assemblages of Giardia have been reported almost exclusively in animal species: 
assemblages C and D in domestic and wild canids, assemblage F in cats, and assemblage E 
in ruminants. Therefore, G duodenalis is considered a multispecies complex, where 
assemblages A and B are considered to have broad host specificity and zoonotic 
potential.86–89
Clinical Manifestations
Approximately 40% of Giardia infections may be symptomatic, depending on the 
population. Symptoms may include diarrhea, cramps, bloating, nausea, and vomiting6 and 
may be prolonged. Infections are normally self-limiting, but chronic diarrhea may occur in 
children90 and a low proportion of immunocompromised people.91 There is a report that 
prolonged giardiasis from early childhood has been associated with poor cognitive function 
later in life.92
Treatment of infections is recommended only when clinical manifestations affect the well-
being of the infected person. Drug of choice is metronidazole, although search for 
alternative therapies is ongoing.93
Diagnostic Testing
Microscopy—Because cysts are shed sporadically during an infection, detection of 
Giardia may require several stool samples to be examined.7,9 Giardia may be detected by 
microscopy, immunologic, or molecular methods. Giardia cysts and trophozoites can be 
readily detected via traditional methods such as trichrome staining and FEA concentrations 
(Fig. 3), although microscopy of whole organisms requires trained technicians as well as 
time to prepare and examine smears. The formalin-ether (Ritchie) concentration method is 
another common method used for the concentration of stool samples.55
Antigen detection and rapid/point-of-care diagnosis—These assays are 
standardized and can generate results in a short time. Tests more widely used are antigen 
detection immunoassays such as DFA tests that detect whole organisms and enzyme 
immunoassays that detect antigens in stool, which can be completed in 1 to 2 hours. They 
have been reported to be highly sensitive and specific (see Table 1B).94,95
PCR assays for Giardia have become more common; however, PCR amplification and 
sequence analysis are more frequently used for genotype/assemblage classification and are 
not routinely used for diagnosis. The SSU rRNA fragment, commonly amplified by PCR for 
other enteric parasites, is rich in GC content and thus requires special PCR conditions. 
Therefore, PCR-based methods have been designed to amplify other informative loci, such 
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as the triose phosphate isomerase, glutamate dehydrogenase, and β-giardin, which are used 
for the taxonomic or epidemiologic classification into assemblages.88,89
SUMMARY ON DETECTION OF PARASITES
Microscopy continues to be the primary method for detection of the parasites covered in this 
review (Table 2), highlighting the importance of specimen processing and staining (see 
Table 2) and morphometric characteristics (Table 3). Rapid diagnostic assays (lateral flow/
immunochromatographic cards) are also available for cryptosporidiosis or giardiasis, 
including approved devices for their simultaneous detection (see Table 1C). At present, 
there are molecular-based assays for the simultaneous detection of multiple enteric 
pathogens, which include virus, bacteria, and parasites. Two of these assays have been 
cleared by FDA and have been reported to have high sensitivity and specificity, including 
the detection of coinfections (see Table 1D).96,97
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APPENDIX 1: LABORATORY PROCEDURES FOR THE MICROSCOPIC 
DETECTION OF COCCIDIAN PARASITES: CRYPTOSPORIDIUM SPP, C 
CAYETANENSIS, AND C BELLI
Modified Kinyoun Acid-Fast Stain
Specimen requirements: unfixed stool or stool preserved in 10% formalin (including FEA concentrates), SAF, or 
EcoFix.
Procedure
1 Prepare a thin film of stool on a glass microscope slide. Allow to completely air dry (do not use heat blocks 
to speed up drying).
2 Fix in absolute methanol for 30 seconds.
3 Stain with carbol-fuschin for 1 minute.
4 Rinse and drain with distilled water.
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5 Decolorize in 10% sulfuric acid (10 mL sulfuric acid in 90 mL absolute ethanol) for 2 minutes.
6 Rinse quickly and drain with distilled water.
7 Counterstain with 3% malachite green (3 g malachite green in 100 mL distilled water) or methylene blue for 
2 minutes.
8 Allow to dry (air dry or on a slide warmer at 60°C).
9 Mount with no. 1 thickness coverslip using Permount (or other sealing reagent).
Procedural notes
• Do not use a slide warmer for the first step (drying of specimen); it cooks the oocysts of Cryptosporidium, 
and they do not retain stain.
• Drain slides between each reagent.
• All reagents should be changed monthly or earlier as needed.
Hot Safranin Stain
Specimen requirements: unfixed stool or stool preserved in 10% formalin (including FEA concentrates), SAF, or 
EcoFix.
Procedure
1 Prepare a thin film of stool on a glass microscope slide. Allow to completely air dry (do not use heat blocks 
to speed up drying).
2 Fix in acid alcohol (3 mL hydrochloric acid in 97 mL absolute methanol) for 5 minutes.
3 Boil in safranin (1% aqueous solution in distilled water) for 1 minute.
4 Counterstain with 3% malachite green (3 g malachite green in 100 mL distilled water) for 1 minute.
5 Allow to dry (air dry or on a slide warmer at 60°C).
6 Mount with no. 1 thickness coverslip using Permount (or other sealing reagent).
Procedural notes
• Do not use a slide warmer for the first step (drying of specimen); it cooks the oocysts of Cryptosporidium, 
and they do not retain stain.
• Drain slides between each reagent.
• All reagents should be changed monthly or earlier as needed.
• Safranin stain should be boiling when slides are added.
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• Sample collection and preservation are important steps, and examination of 3 
specimens from different days increases the accuracy of diagnosis.
• Giardia can be detected by light microscopy during ova-and-parasite (O&P) 
examination, antigen detection methods (laboratory and rapid diagnostic 
devices), or fluorescent microscopy.
• Cryptosporidium and Cyclospora are not easily detectable by O&P examination, 
and parasite-specific tests must be requested, such as modified acid-fast (MAF) 
microscopy. For Cryptosporidium, there are antigen detection assays (laboratory 
or rapid diagnostic devices) or antibody-based fluorescent microscopy. Properly 
equipped fluorescent microscopes can be used in research laboratories for 
confirmation of Cyclospora, as this parasite autofluoresces with the appropriate 
excitation wavelength.
• Cystoisospora can be detected by light microscopy, and confirmation is 
accomplished through morphometric characteristics of samples that have been 
stained with safranin or acid-fast stain and also by autofluorescence.
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Comparison of (A, D) Cryptosporidium spp, (B, E) Cyclospora cayetanensis, and (C, F) 
Cystoisospora belli stained with modified acid-fast and safranin stains, original 
magnification × 1000. (Public domain images, courtesy of DPDx, Centers for Disease 
Control and Prevention, Atlanta, USA).
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Cyclospora cayetanensis oocyst viewed under normal light (left) and ultraviolet light (right) 
in an unstained wet mount. (Original magnification × 1000). (Courtesy of DPDx, Centers for 
Disease Control and Prevention, Atlanta, USA).
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Trophozoite (left) and cyst (right) of Giardia duodenalis (trichrome, original magnification 
× 1000). (Courtesy of DPDx, Centers for Disease Control and Prevention, Atlanta, USA.)
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Table 2
Microscopy procedures for detection of Cryptosporidium spp, Cyclospora cayetanensis, and Cystoisospora 
belli
Procedure Parasite Advantages Disadvantages
Wet mount (FEA 
concentrates)
Cryptosporidium spp Concentration allows for better yield
FEA concentrate can be used for 
DFA (see later in the table)
Oocysts may be confused for yeast and 
other nonparasitic elements
Formalin waste
Cyclospora cayetanensis Concentration allows for better yield
May be enhanced with differential 
interference contrast (DIC) or phase 
microscopy
Oocysts may be confused with 
nonparasitic elements
Formalin waste
Cystoisospora belli Concentration allows for better yield
May be enhanced with DIC or phase 
microscopy
Oocysts shed sporadically so multiple 
collections should be tested
Formalin waste
Trichrome stain Cryptosporidium spp Not recommended Oocysts do not stain well with trichrome; 
likely to be confused for yeast/fungal 
elements
Specimens in PVA usually not 
concentrated
Cyclospora cayetanensis Not recommended Oocysts do not stain well with trichrome
Specimens in PVA usually not 
concentrated
Cystoisospora belli Not recommended Not readily detected by trichrome
Specimens in PVA usually not 
concentrated
Modified Kinyoun acid-fast 
(MAF) stain
Cryptosporidium spp Uniform staining of oocysts; 
sporozoites often visible
Oocysts may be confused with yeast and 
other fungal elements that often stain red 
to purple with MAF
Cyclospora cayetanensis Oocysts can stain pink to red Variability in staining; often many 
oocysts do not stain (ghost forms) and 
may be overlooked by inexperienced 
microscopists
Cystoisospora belli Sporoblasts stain red with MAF Often there is shrinkage of oocyst wall, 
distorting form of oocysts
Hot safranin stain Cryptosporidium spp Uniform staining of oocysts Requires heat; messy procedure
Cyclospora cayetanensis More uniform staining of oocysts Requires heat; messy procedure
Cystoisospora belli Uniform staining of sporoblasts
Oocyst wall less likely to collapse 
than with MAF
Requires heat; messy procedure
Ultraviolet microscopy Cryptosporidium spp Not available Oocysts do not autofluoresce
Cyclospora cayetanensis Oocyst walls autofluoresce
Allows for more rapid screening
Requires special filter with wavelength of 
450–490 nm (not routine in most 
laboratories)
Cystoisospora belli Oocyst and sporoblast walls 
autofluoresce
Allows for more rapid screening
Requires special filter with wavelength of 
450–490 nm (not routine in most 
laboratories)
DFA Cryptosporidium spp Allows for rapid screening of 
Cryptosporidium spp
Some allow for simultaneous 
screening of other organisms (eg, 
Giardia)
Requires microscopy with fluorescence 
capabilities
Could be expensive if not used routinely
Cyclospora cayetanensis None available None available
Cystoisospora belli None available None available
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Table 3
Comparative morphology of Giardia duodenalis, Cryptosporidium spp, Cyclospora cayetanensis, and 
Cystoisospora belli
Organism Size Other Morphologic Features
Preferred Morphologic 
Diagnostic Test
Giardia duodenalis Trophozoites, 10–20 μm 
long
Cysts 8.0–10 μm long
Trophozoites: pyriform shape; sucking disk; 2 nuclei; 
2 median bodies; 8 flagella (4 lateral, 2 ventral, 2 
posterior)
Cysts: ovoid shape; 2–4 nuclei; fibrils and median 
bodies; no flagella
Trophozoites: direct wet 
mount; trichrome stain
Cysts: FEA concentration 
wet mount; trichrome stain
Cryptosporidium spp Oocysts: 4.0–6.0 μm Oocysts: spherical shape; sporulated in feces (4 
sporozoites present)
Modified acid-fast stain; 
Safranin stain
Cyclospora cayetanensis Oocysts: 8.0–10 μm Oocysts: spherical; unsporulated in fresh feces; 
refractile globules present
Modified acid-fast stain; 
Safranin stain; UV 
microscopy
Cystoisospora belli Oocysts: 20–33 μm long Oocysts: oval to ellipsoidal shape; unsporulated in 
fresh feces; double-layered hyaline cyst wall; single 
sporoblast usually present
Modified acid-fast stain; 
safranin stain; UV 
microscopy
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